Abstract:
Deep vein thrombosis (DVT), caused by alterations in venous homeostasis is the third most common cause of cardiovascular mortality; however, key molecular determinants in venous thrombosis have not been fully elucidated. Several lines of evidence indicate that DVT occurs at the intersection of dysregulated inflammation and coagulation. The enzyme ectonucleoside tri(di)phosphohydrolase (ENTPD1, also known as CD39) is a vascular ecto-apyrase on the surface of leukocytes and the endothelium that inhibits intravascular inflammation and thrombosis by hydrolysis of phosphodiester bonds from nucleotides released by activated cells.
Here, we evaluated the contribution of CD39 to venous thrombosis in a restricted-flow model of murine inferior vena cava stenosis. CD39-deficiency conferred a >2-fold increase in venous thrombogenesis, characterized by increased leukocyte engagement, neutrophil extracellular trap formation, fibrin and local activation of tissue factor in the thrombotic milieu. This was orchestrated by increased phosphorylation of the p65 subunit of NFκB, activation of the NLRP3 inflammasome, and interleukin-1β (IL-1β) release in CD39-deficient mice. Substantiating these findings, an IL-1β-neutralizing antibody attenuated the thrombosis risk in CD39-deficient mice.
These data demonstrate that IL-1β is a key accelerant of venous thrombo-inflammation, which can be suppressed by CD39. CD39 inhibits in vivo crosstalk between inflammation and coagulation pathways, and is a critical vascular checkpoint in venous thrombosis.
Introduction:
The cell surface enzyme ectonucleoside tri(di)phosphohydrolase-1 (ENTPD1, also known as CD39), is a key molecular factor protecting blood fluidity at the vessel-wall interface by catalyzing the hydrolytic cleavage of phosphodiester bonds, thereby dissipating the extracellular purinergic nucleotides ATP and ADP. These extracellular purines function as intravascular autocrine and paracrine "danger" signals to a variety of cells including innate immune cells, platelets, and endothelium, activating inflammatory and thrombotic pathways.(1, 2) Our group has recently shown that CD39 haploinsuffficiency is a critical mediator of arterial leukocyte trafficking, atherosclerosis, and platelet hyperactivity, (3) (4) (5) but the role for CD39 in the venous milieu has not been fully elucidated; in contrast to arterial beds, veins are characterized by low shear, absence of atherosclerotic plaque, and an emphasis on tissue factordriven thrombosis. Despite the substantial morbidity and mortality burden of deep venous thrombosis,(6) proximate mechanisms that trigger and propagate venous thrombosis are incompletely understood. As a window to understanding venous thrombosis pathogenesis, many acquired risk factors are associated with DVT, including trauma, infection, and chronic inflammatory diseases suggesting an integral association between inflammation and coagulation.(7) Although multiple, sometimes coalescing pathologic drivers can result in venous thrombosis, current studies have largely focused on coagulation, while the precise mechanisms underlying inflammatory triggers and their endogenous checkpoints remain unknown. We hypothesized that CD39 haploinsufficient mice would have impaired protection against DVT, enhanced leukocyte recruitment and activation, and unrestrained inflammatory signaling.
Here, we show that CD39 plays a critical role in protection from venous thrombogenesis 
CD39 haploinsufficiency increases neutrophil extracellular trap formation in venous thrombosis.
We next examined whether the increased thrombogenesis in Cd39 +/-mice could in part be explained by leukocyte engagement. Venous thrombi in Cd39 +/-mice revealed enhanced leukocyte recruitment, driven primarily by neutrophils (Figure 2A 
